Stifel Says Fulcrum Therapeutics’ 12% Pullback Overdone; $28 Target Maintained
Stifel flagged that Fulcrum Therapeutics share price decline of over 12% since early February is excessive and reiterated its Buy rating with a $28 price target, citing confidence in the company's fibrosis-focused pipeline. The firm highlighted upcoming Phase II results for its lead program as a key midyear catalyst.
1. Stifel Analysis
Stifel’s equity research team noted a 12% decline in Fulcrum Therapeutics shares since early February and described the sell-off as overdone relative to the company's clinical progress. The firm maintained a Buy rating and $28 price target, citing confidence in the fibrosis-focused pipeline and upcoming Phase II data as potential share-price catalysts.
Related News
QQQ
Nasdaq-100 ETF Trackers Eye 30% EM Earnings Growth and Nvidia’s $78.8B Quarter
QQQ•
PYPL
PayPal Expands PYUSD Stablecoin to 70 Markets for Instant Global Payments
PYPL•
MMYT
MakeMyTrip Q4 Cash Hits $782M with 1.82% Margin and 15.2% Accommodation Growth
MMYT•
PEP
PepsiCo to raise single-serve chip bag prices by 10–20 cents in June
PEP•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
Sources
F